MONTREAL, CANADA--(CCNMatthews - April 10, 2006) - ProMetic BioSciences Inc., the therapeutic unit of ProMetic Life Sciences Inc. (TSX:PLI.SV), announced today that it has started enrollment of patients for its Phase Ib/II clinical trial of PBI-1402. The study is designed to monitor the safety and efficacy of its compound in cancer patients undergoing chemotherapy and suffering from anemia.
